In the high-risk world of early-phase drug development in the pharmaceutical industry, traditional forecasting methods often fail to account for clinical, commercial, and regulatory uncertainties. This Point of View report reveals how innovative approaches—powered by AI and advanced analytics—are transforming how pharmaceutical companies:
- Quantify risks for preclinical to Phase II assets
- Optimize portfolio resource allocation
- Prepare for multiple future scenarios
Featuring insights from Axtria’s forecasting experts with 20+ years combined in pharmaceutical analytics.
Featured experts
Key highlights
Drawing on their extensive experience guiding top pharma companies, Pullarkat and Meena have structured their insights around four pivotal questions.
- Why is early-stage forecasting such a challenge for pharma companies?
- How can scenario planning reveal hidden risks and opportunities?
- Which variables matter most while performing sensitivity analyses?
- Will AI and probabilistic thinking redefine the traditional approach to risk management?
Contact us at connect@axtria.com with any questions.
FAQs
Recommended insights
Article
Article
Article